The reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.42BCNY
662.33M · vs all stocks (USD)
Updated Nov 20, 2026
Revenue (TTM)
6.52BCNY
977.33M · vs all stocks (USD)
Updated Nov 20, 2026
Profit Margin
-8.57%
vs Diagnostics & Research peers
Updated Nov 20, 2026
Beta
0.6350x
vs all stocks
Updated Nov 20, 2026
52-Week Change
-54.62%
vs all stocks
Updated Nov 20, 2026
Market Capitalization
4.42BCNY
662.33M · vs all stocks (USD)
Updated Nov 20, 2026
Enterprise Value
10.81BCNY
1.62B · vs all stocks (USD)
Updated Nov 20, 2026
Forward P/E
10.22x
vs Diagnostics & Research peers
Updated Nov 20, 2026
Price to Sales (TTM)
0.6916x
vs Diagnostics & Research peers
Provider-reported. Market Capitalization ÷ Revenue (TTM) on this page gives 0.68×.Updated Nov 20, 2026
Price to Book (MRQ)
1.25x
vs Diagnostics & Research peers
Updated Nov 20, 2026
Enterprise to Revenue
1.66x
vs Diagnostics & Research peers
Updated Nov 20, 2026
Enterprise to EBITDA
33.93x
vs Diagnostics & Research peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 18.58×.Updated Nov 20, 2026
Gross Margin
25.61%
vs Diagnostics & Research peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 22.77%.Updated Nov 20, 2026
Profit Margin
-8.57%
vs Diagnostics & Research peers
Updated Nov 20, 2026
Operating Margin
1.08%
vs Diagnostics & Research peers
Updated Nov 20, 2026
Return on Assets (TTM)
0.34%
vs Diagnostics & Research peers
Updated Nov 20, 2026
Return on Equity (TTM)
-10.91%
vs Diagnostics & Research peers
Updated Nov 20, 2026
Revenue (TTM)
6.52BCNY
977.33M · vs all stocks (USD)
Updated Nov 20, 2026
Revenue per Share (TTM)
10.89CNYUpdated Nov 20, 2026
Quarterly Revenue Growth
-11.10%
vs Diagnostics & Research peers
Updated Nov 20, 2026
Gross Profit (TTM)
1.49BCNY
222.57M · vs all stocks (USD)
Updated Nov 20, 2026
EBITDA (TTM)
581.92MCNY
87.21M · vs all stocks (USD)
Updated Nov 20, 2026
Net Income (TTM)
-558.96MCNY
-83.77M · vs all stocks (USD)
Updated Nov 20, 2026
Quarterly Earnings Growth (YoY)
1.29%
vs Diagnostics & Research peers
Updated Nov 20, 2026
Operating Cash Flow (TTM)
922.96MCNY
138.31M · vs all stocks (USD)
Updated Nov 20, 2026
Levered Free Cash Flow (TTM)
1.17BCNY
175.46M · vs all stocks (USD)
Updated Nov 20, 2026
5-Year Average Dividend Yield
0.44%
vs all stocks
Updated Nov 20, 2026
Payout Ratio
111.11%
vs Diagnostics & Research peers
Updated Nov 20, 2026
Minority Interest (Equity)
1.10BCNYFY2025 · Dec 31, 2025
Revenue
7.00BCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
5.50BCNYFY2025 · Dec 31, 2025
Gross Profit
1.50BCNYFY2025 · Dec 31, 2025
Operating Income
204.62MCNY
30.66M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-460.64MCNYFY2025 · Dec 31, 2025
Income Tax Expense
57.51MCNYFY2025 · Dec 31, 2025
Net Income
-518.15MCNYFY2025 · Dec 31, 2025
EBIT
-181.71MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
581.92MCNYFY2025 · Dec 31, 2025
Research & Development
108.01MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
438.77MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
112.91MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
10.98MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
278.93MCNYFY2025 · Dec 31, 2025
EPS (Basic)
-0.9100CNYFY2025 · Dec 31, 2025
EPS (Diluted)
-0.9100CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
602.63MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
602.63MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-518.15MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
-30.24MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
-858.12MCNYFY2025 · Dec 31, 2025
Free Cash Flow
-1.09BCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
667.05MCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-518.15MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
307.94MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-70.25MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-577.67MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-232.67MCNYFY2025 · Dec 31, 2025
Purchase of Investments
-559.78MCNYFY2025 · Dec 31, 2025
Sale of Investments
552.12MCNYFY2025 · Dec 31, 2025
Other Investing Activity
856.96KCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-239.46MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
7.58BCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-7.69BCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-281.35MCNYFY2025 · Dec 31, 2025
Other Financing Charges
-92.19MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
-479.76MCNYFY2025 · Dec 31, 2025
Shares Outstanding
604.60MSharesUpdated Nov 20, 2026
Float Shares
416.99MSharesUpdated Nov 20, 2026
% Held by Insiders
32.86%
vs all stocks
Updated Nov 20, 2026
% Held by Institutions
1.85%
vs all stocks
Updated Nov 20, 2026
Total Cash (MRQ)
717.72MCNY
107.56M · vs all stocks (USD)
Updated Nov 20, 2026
Total Cash per Share (MRQ)
1.19CNYUpdated Nov 20, 2026
Total Debt (MRQ)
5.81BCNY
870.85M · vs all stocks (USD)
Updated Nov 20, 2026
Total Debt to Equity (MRQ)
1.28x
vs Diagnostics & Research peers
Updated Nov 20, 2026
Current Ratio (MRQ)
1.03x
vs Diagnostics & Research peers
Updated Nov 20, 2026
Book Value per Share (MRQ)
5.96CNYUpdated Nov 20, 2026
Total Assets
13.42BCNY
2.01B · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
8.52BCNYFY2025 · Dec 31, 2025
Total Liabilities
8.54BCNYFY2025 · Dec 31, 2025
Total Non-current Assets
4.90BCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
857.58MCNYFY2025 · Dec 31, 2025
Total Current Liabilities
7.68BCNYFY2025 · Dec 31, 2025
Cash
667.05MCNYFY2025 · Dec 31, 2025
Cash Equivalents
348.80MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
1.02BCNYFY2025 · Dec 31, 2025
Other Short-term Investments
129.80MCNYFY2025 · Dec 31, 2025
Accounts Receivable
4.46BCNYFY2025 · Dec 31, 2025
Inventory
1.73BCNYFY2025 · Dec 31, 2025
Accounts Payable
1.22BCNYFY2025 · Dec 31, 2025
Short-term Debt
6.06BCNYFY2025 · Dec 31, 2025
Other Current Liabilities
21.46MCNYFY2025 · Dec 31, 2025
Long-term Debt
708.16MCNYFY2025 · Dec 31, 2025
Other Non-current Liabilities
5.69MCNYFY2025 · Dec 31, 2025
Common Stock (Book)
603.68MCNYFY2025 · Dec 31, 2025
Retained Earnings
1.77BCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
4.88BCNY
731.54M · vs all stocks (USD)
FY2025 · Dec 31, 2025
52-Week Low
7.30CNYUpdated Nov 20, 2026
52-Week High
20.77CNYUpdated Nov 20, 2026
52-Week Change
-54.62%
vs all stocks
Updated Nov 20, 2026
Beta
0.6350x
vs all stocks
Updated Nov 20, 2026
50-Day MA
9.76CNYUpdated Nov 20, 2026
200-Day MA
11.51CNYUpdated Nov 20, 2026
Avg 10-Day Volume
23.35MSharesUpdated Nov 20, 2026
Avg 30-Day Volume
22.41MSharesUpdated Nov 20, 2026
Diluted EPS (TTM)
-0.8600CNYUpdated Nov 20, 2026
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Down-Close Share With Multi-Year Earnings Decrease
Most weeks closed down this year, and earnings and gross profit fell over four.
Reads
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.